Search results
Results from the WOW.Com Content Network
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Etrolizumab was developed by Genentech [2] [3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells. [4] As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4] A Phase I clinical trial found that it was well tolerated by healthy subjects. [5]
For premium support please call: 800-290-4726 more ways to reach us
Genentech, Roche HER2-positive metastatic breast cancer (mBC) following treatment with trastuzumab and a maytansinoid: Inotuzumab ozogamicin: Besponsa Pfizer/Wyeth: relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia: Polatuzumab vedotin: Polivy Genentech, Roche relapsed or refractory diffuse large B-cell lymphoma ...